Biotech start-up Danube Pharmaceuticals Inc. has in-licensed what it calls the only dual-mechanism of action, orally available small molecule in clinical testing for glaucoma, a leading cause of irreversible blindness worldwide.
c/o Two River Group Holdings
689 Fifth Avenue
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.
After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.
Swiss major confident that new oncology drugs will fill revenue gap.
